Related Experiment Video
Updated: Dec 30, 2025
miRNA Expression Analyses in Prostate Cancer Clinical Tissues
Published on: September 8, 2015
miR-27b expression in diagnosis and evaluation prognosis of prostate cancer
Tian Li1,2, Xiangzhou Sun3, Yifan Liu1,2
1Department of Urology, The Fifth Affiliated Hospital of Guangzhou Medical University Guangzhou 510700, Guangdong, China.
Objective:
The aim of study was to investigate the expression of microRNA-27b in different prostate tissues and its anti-tumor effects in prostate cancer.
Methods:
Measuring the expression of microRNA-27b, evaluating the PI3K protein expression in 28 benign prostatic hyperplasia and 63 prostate cancer tissues, analyzing the correlation between miRNA-27b and PI3K, and miRNA-27b's correlation with Gleason Grading and clinical stages were analyzed. We divided the prostate cancer patients into two groups: low group and high group, comparing the overall survival and progression free survival. In the cell experiment, the PC3 was divided into three groups: NC group, BL group and miRNA group. The cells of difference groups were measuring the cell proliferation, apoptosis and cycle and evaluating PI3K, AKT and P21 protein expressions of difference groups.
Results:
The microRNA-27b expression of prostate cancer significantly increased Compared with benign prostatic hyperplasia (P<0.05). The PI3K protein expression of prostate cancer tissues were significantly enhanced compared with benign prostatic hyperplasia. The PI3K protein expression was positive correlation with miRNA-27b in cancer tissues. Furthermore, the microRNA-27b expression was significantly correlated with the Gleason Grading and clinical stages in prostate cancer (P<0.05, respectively). The patients with higher miR-27b expression level had both poorer overall survival and progression free survival. In cell experiment, the cell proliferation of miRNA group was significantly lower than NC group (P<0.05); the cell apoptosis and G1 phase of miRNA group were significantly difference compared with NC group (P<0.05, respectively); Compared with NC group, PI3K, AKT and P21 protein expressions were significantly down-regulation in miRNA group (P<0.05, respectively).
Conclusions:
miR-27b was up-regulated in prostate cancer tissue compared with benign prostatic hyperplasia tissues, and its expression level was correlated with a variety of important clinical pathological parameters. In the treatment of prostate cancer, miR-27b inhibition had effects to suppress prostate cancer proliferation by regulation PI3K/AKT/P21 signaling pathway. Moreover; miR-27b may serve as a promising biomarker for predicting the prognosis of prostate cancer.
Insights
MicroRNA-27b is elevated in prostate cancer, correlating with poorer prognosis and suppressed proliferation via the PI3K/AKT/P21 pathway. This microRNA may serve as a predictive biomarker for prostate cancer outcomes.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Prostate cancer is a significant global health concern.
- Understanding the molecular mechanisms underlying prostate cancer progression is crucial for developing effective therapies.
Purpose of the Study:
- To investigate the expression levels of microRNA-27b in prostate tissues.
- To evaluate the anti-tumor effects of microRNA-27b in prostate cancer.
- To explore the correlation between microRNA-27b and key clinical pathological parameters.
Main Methods:
- MicroRNA-27b and PI3K protein expression were measured in benign prostatic hyperplasia and prostate cancer tissues.
- Correlations with Gleason Grading, clinical stages, overall survival, and progression-free survival were analyzed.
- In vitro studies assessed cell proliferation, apoptosis, cell cycle, and protein expression (PI3K, AKT, P21) in PC3 cells.
Main Results:
- MicroRNA-27b expression was significantly higher in prostate cancer than in benign tissues.
- Elevated microRNA-27b correlated with increased PI3K expression, advanced Gleason Grading, and later clinical stages.
- Higher microRNA-27b levels were associated with poorer overall and progression-free survival.
- In vitro, microRNA-27b inhibition suppressed cell proliferation and induced apoptosis, downregulating PI3K/AKT/P21 signaling.
Conclusions:
- MicroRNA-27b is upregulated in prostate cancer and linked to adverse clinical outcomes.
- Inhibition of microRNA-27b demonstrates anti-proliferative effects by modulating the PI3K/AKT/P21 pathway.
- MicroRNA-27b shows potential as a prognostic biomarker for prostate cancer.
